Debate: Preventing diabetic complications – 100 years on from insulin: Which of the newer classes will prevail?
Friday, 1 October 2021, 10:00 - 11:00, Madrid Hall
Chair: R.K. Semple, UK
M.A. Nauck, DE: 100 years later, it’s GLP-1 receptor agonists
J.P.H. Wilding, UK: 100 years later, it’s SGLT2 inhibitors